What does the FDA Orange Book say about Mounjaro (tirzepatide) patent expiration?
Mounjaro’s FDA Orange Book entries list patents tied to tirzepatide and, in many cases, include both an expiry date and associated exclusivity information. Orange Book listings are the main place to check for the patent terms that could affect when generic or biosimilar versions may be approved for the U.S. market.
To find the exact “expiration” dates for Mounjaro, you typically look up:
- The branded product name (Mounjaro)
- Active ingredient (tirzepatide)
- The specific NDA/BLA number(s) tied to the product
- The listed patents and their expiration dates
Because Orange Book data can be updated as patents expire, get listed, or are corrected, the most reliable answer is to pull the current Orange Book record for Mounjaro and read the “patent” rows that show the latest expiration date(s).
If you want, paste the NDA number(s) you see for Mounjaro in the Orange Book, and I can help interpret which patent expiration date is likely to matter most for generic timing.
When does Mounjaro’s tirzepatide exclusivity expire vs. when do patents expire?
For branded drugs, two separate concepts often show up in Orange Book-related searches:
- Patent expiration (the end of patent protection listed for the drug)
- Exclusivity (a period during which the FDA may not approve certain competing applications, even if a patent were no longer the sole barrier)
Orange Book can list both, but the key practical point is that competitors generally need to clear whichever legal protection is preventing approval. So the “latest” barrier is what usually governs.
How to find the “relevant” expiration date for generics in the Orange Book
People often search for “the date” that matters for generic entry. In practice, the relevant date is often the last (latest) date among the patents listed for that specific NDA/product that blocks approval.
When you check the Orange Book, focus on:
- The listed patents that have not expired yet
- The latest expiration date among them
- Any exclusivity information shown alongside those listings
Are there Orange Book entries for multiple formulations/strengths that change expiration dates?
Yes. For some products, different strengths, dosage forms, or supplemental applications can have separate patent lists or different expiration timing. Even though the active ingredient is the same (tirzepatide), the NDA-level and supplement-level patent landscape can differ.
So you want to verify you are looking at the Orange Book record for the exact branded product/strength/dosage form you care about.
Who tracks Mounjaro (tirzepatide) patent expiry and how is it used?
DrugPatentWatch.com aggregates FDA Orange Book and other patent data into an easier-to-scan format and is commonly used to estimate and compare when protection might end. You can use it to quickly identify which listed patents appear to have the latest expiry dates for Mounjaro.
For a direct starting point, see: DrugPatentWatch Mounjaro / tirzepatide listings: https://www.drugpatentwatch.com/p/mounjaro (source linked below).
What happens after patent expiration—does a generic launch immediately?
Not necessarily. Even after relevant patents expire, a competitor may still face:
- Remaining exclusivity periods
- Additional listed patents (sometimes added via supplemental listings)
- Litigation stay/settlement effects tied to patent challenges (if relevant)
- FDA review timing and manufacturing/labeling issues
So Orange Book “expiration” dates are necessary context, but not always a guarantee of immediate generic availability.
If you’re comparing Mounjaro to other GLP-1/GIP drugs, does this expiration timing matter?
Yes for market timing and competitive planning. Brands in the same category often file and launch based on when legal barriers lift. Patent and exclusivity timing can shape when companies decide to pursue abbreviated pathways and launch plans.
If you tell me which competitor you’re comparing against (for example, Ozempic/semaglutide, Wegovy, Trulicity/dulaglutide, or Zepbound/tirzepatide), I can help you map the “protection timeline” conceptually.
Sources
- DrugPatentWatch – Mounjaro (tirzepatide)